Skip to main content

Advertisement

SpringerLink
Log in

Effectiveness of polypoidal lesion-selective photodynamic therapy with intravitreal antivascular endothelial growth factor for polypoidal choroidal vasculopathy

  • Clinical Investigation
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the 24-month effectiveness of polypoidal lesion-selective photodynamic therapy (PDT) combined with antivascular endothelial growth factor (VEGF) therapy for polypoidal choroidal vasculopathy (PCV) with branching vascular networks (BVNs) involving the fovea with 1 or more polyps.

Study design

A retrospective case series.

Patients and methods

Twenty-six eyes from 25 PCV patients treated with polypoidal lesion-selective PDT combined with aflibercept were included in the study. The main outcome measure was change in best-corrected visual acuity (BCVA), and the secondary outcome measures were changes in central retinal thickness and subfoveal choroidal thickness on optical coherence tomography (OCT), status of exudation at 24 months, and number of additional treatments.

Results

Fourteen eyes of 14 patients showed treatment-naïve PCV, and 12 eyes of 11 patients were switched from anti-VEGF monotherapy. The baseline mean logMAR BCVA was 0.43, and this had increased significantly, by 0.31, at 24 months (P = .034). The mean central retinal thickness (CRT) and central choroidal thickness (CCT) were significantly lower at all time points than those at baseline. The mean number of additional injections of aflibercept was 3.1 (range, 0–9), and that of additional PDT treatments was 0.5 (range, 0–2).

Conclusion

Polypoidal lesion-selective PDT with aflibercept was effective for relatively large, fovea-involved PCV, with significant visual improvement at 24 months.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Spaide RF, Yannuzzi LA, Slakter JS, Sorenson J, Orlach DA. Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina. 1995;15:100–10.

    Article  CAS  Google Scholar 

  2. Yamamoto A, Okada AA, Kano M, Koizumi H, Saito M, Maruko I, et al. One-year results of intravitreal aflibercept for polypoidal choroidal vasculopathy. Ophthalmology. 2015;122:1866–72.

    Article  Google Scholar 

  3. Chan W-M, Lam DS, Lai TY, Liu DT, Li KK, Yao Y, et al. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy. Ophthalmology. 2004;111:1576–84.

    Article  Google Scholar 

  4. Gomi F, Ohji M, Sayanagi K, Sawa M, Sakaguchi H, Oshima Y, et al. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese Patients. Ophthalmology. 2008;115:141–6.

    Article  Google Scholar 

  5. Honda S, Imai H, Yamashiro K, Kurimoto Y, Kanamori-Matsui N, Kagotani Y, et al. Comparative assessment of photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: a multicenter study in Hyogo prefecture. Japan. Ophthalmologica. 2009;223:333–8.

    Article  Google Scholar 

  6. Lee MY, Lee K, Baek J, Kwon OW, Lee H. Photodynamic therapy versus combination therapy in polypoidal choroidal vasculopathy: changes of aqueous vascular endothelial growth factor. Am J Ophthalmol. 2013;156:343–8.

    Article  CAS  Google Scholar 

  7. Lai TYY, Lee GKY, Luk FOJ, Lam DSC. Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy. Retina. 2011;31:1581–8.

    Article  CAS  Google Scholar 

  8. Takayama K, Kaneko H, Kataoka K, Hattori K, Ra E, Tsunekawa T, et al. Comparison between 1-year outcomes of aflibercept with and without photodynamic therapy for polypoidal choroidal vasculopathy: retrospective observation study. PLoS One. 2017;12:1–12.

    Article  Google Scholar 

  9. Schmidt-Erfurth U, Michels S, Barbazetto I, Laqua H. Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci. 2002;43:830–41.

    PubMed  Google Scholar 

  10. Schmidt-Erfurth U, Laqua H, Schlötzer-Schrehard U, Viestenz A, Naumann GOH. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol. 2002;120:835–44.

    PubMed  Google Scholar 

  11. Cheung CMG, Lai TYY, Ruamviboonsuk P, Chen SJ, Chen Y, Freund KB, et al. Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management. Ophthalmology. 2018;125:708–24.

    Article  Google Scholar 

  12. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials–TAP report. Arch Ophthalmol. 1999;117:1329–45.

  13. Tsujikawa A, Ojima Y, Yamashiro K, Nakata I, Ooto S, Tamura H, et al. Association of lesion size and visual prognosis to polypoidal choroidal vasculopathy. Am J Ophthalmol. 2011;151:961–72.

    Article  Google Scholar 

  14. Suzuki M, Nagai N, Shinoda H, Uchida A, Kurihara T, Tomita Y, et al. Distinct responsiveness to intravitreal ranibizumab therapy in polypoidal choroidal vasculopathy with single or multiple polyps. Am J Ophthalmol. 2016;166:52–9.

    Article  CAS  Google Scholar 

  15. Suzuki M, Gomi F, Sawa M, Ueno C, Nishida K. Changes in fundus autofluorescence in polypoidal choroidal vasculopathy during 3 years of follow-up. Graefe’s Arch Clin Exp Ophthalmol. 2013;251:2331–7.

    Article  Google Scholar 

  16. Koh A, Lai TYY, Takahashi K, Wong TY, Chen L-J, Ruamviboonsuk P, et al. Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial. JAMA Ophthalmol. 2017;135:1206–13.

    Article  Google Scholar 

  17. Kikushima W, Sakurada Y, Sugiyama A, Tanabe N, Kume A, Iijima H. Comparison of initial treatment between 3-monthly intravitreal aflibercept monotherapy and combined photodynamic therapy with single intravitreal aflibercept for polypoidal choroidal vasculopathy. Graefe’s Arch Clin Exp Ophthalmol. 2017;255:311–6.

    Article  CAS  Google Scholar 

  18. Mori R, Yuzawa M, Akaza E, Haruyama M. Treatment results at 1 year of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good visual acuity. Jpn J Ophthalmol. 2013;57:365–71.

    Article  CAS  Google Scholar 

  19. Miyata M, Ooto S, Yamashiro K, Tamura H, Hata M, Ueda-Arakawa N, et al. Five-year visual outcomes after anti-VEGF therapy with or without photodynamic therapy for polypoidal choroidal vasculopathy. Br J Ophthalmol. 2018.

  20. Wakabayashi T, Gomi F, Sawa M, Tsujikawa M, Tano Y. Marked vascular changes of polypoidal choroidal vasculopathy after photodynamic therapy. Br J Ophthalmol. 2008;92:936–40.

    Article  CAS  Google Scholar 

  21. Lai TY, Chan WM, Lam DS. Transient reduction in retinal function revealed by multifocal electroretinogram after photodynamic therapy. Am J Ophthalmol. 2004;137:826–33.

    Article  Google Scholar 

  22. Park SJ, Choi Y, Na YM, Hong HK, Park JY, Park KH, et al. Intraocular pharmacokinetics of intravitreal aflibercept (Eylea) in a rabbit model. Invest Ophthalmol Vis Sci. 2016;57:2612–7.

    Article  CAS  Google Scholar 

  23. Nakai S, Matsumiya W, Otsuka K, Miki A, Nakamura M, Honda S. The 24-month outcomes of intravitreal aflibercept combined with photodynamic therapy for polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2019;63:100–8.

    Article  CAS  Google Scholar 

  24. Maruko I, Iida T, Sugano Y, Ojima A, Ogasawara M, Spaide RF. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology. 2010;117:1792–9.

    Article  Google Scholar 

  25. Maruko I, Iida T, Oyamada H, Sugano Y, Ojima A, Sekiryu T. Choroidal thickness changes after intravitreal ranibizumab and photodynamic therapy in recurrent polypoidal choroidal vasculopathy. Am J Ophthalmol. 2013;156:548–56.

    Article  CAS  Google Scholar 

  26. Gomi F, Oshima Y, Mori R, Kano M, Saito M, Yamashita A, et al. Initial versus delayed photodynamic therapy in combination with ranibizumab for treatment of polypoidal choroidal vasculopathy. Retina. 2015;35:1569–76.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan

    Yuki Komuku & Fumi Gomi

  2. Department of Ophthalmology, Sumitomo Hospital, Osaka, Japan

    Chiharu Iwahashi & Fumi Gomi

Authors
  1. Yuki Komuku
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chiharu Iwahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fumi Gomi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fumi Gomi.

Ethics declarations

Conflicts of interest

Y. Komuku, None; C. Iwahashi, None; F. Gomi, Grant (Pfizer, Alcon Japan, Novartis International AG, Otsuka), Speaker fee (Bayer Yakuhin), Lecture fee (Pfizer, Alcon Japan, Novartis International AG, Otsuka, Santen, SENJU, GlaxoSmithKline K.K.).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Corresponding Author: Fumi Gomi

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Komuku, Y., Iwahashi, C. & Gomi, F. Effectiveness of polypoidal lesion-selective photodynamic therapy with intravitreal antivascular endothelial growth factor for polypoidal choroidal vasculopathy. Jpn J Ophthalmol 64, 265–270 (2020). https://doi.org/10.1007/s10384-020-00734-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-020-00734-3

Keywords

Search

Navigation